Browse diseases

…January and July 2025. It included patients aged ≥18 years with moderate-to-severe psoriasis receiving biologic therapy for at least 6 months. Patients with…

…e-mediated diseases such as psoriasis, psoriatic arthritis, and axial spondyloarthritis. Secukinumab, a fully human IgG1κ antibody, and ixekizumab, a h…

… a Belgian University Hospital, centred around the treatment of psoriasis, including the management of associated comorbidities.Participa…

…ertolizumab, another TNF-α inhibitor, for the management of her psoriasis, having previously trialled other biologics. Thereafter, she de…

… Denosumab Osteoporosis 44 Nil Yes No 5 Benralizumab Adalimumab Rheumatoid Arthritis 24 Nil Yes No Benralizumab Adalimumab Ankylosing Spondylitis 5 …

…Samson CM. Immunosuppressant-associated eruptions in paediatric inflammatory bowel disease: a case-control study. Journal article. 2022.Cossio ML, Genois …

…were first approved by our trust for treatment of patients with Ulcerative Colitis (UC), Crohn’s Disease (CD) and IBD-U in 2018, before blueteq ap…

…sis for SSc provides insights into a novel disease mechanism of SSc, particularly in light of its unexpected association with Pso.A…

…ed approach.Here we report a rare case of a patient affected by Systemic sclerosis (SSc), inflammatory myopathy and psoriatic arthritis successfully tre…

…ith increased local inflammation in various conditions, such as rheumatoid arthritis, psoriasis, and systemic lupus erythematosus. Its role in syste…

…py was significantly associated with a reduced risk of incident PsA compared with TNF inhibitors.…

…association between psoriasis and the subsequent development of granulomatous prostatitis and the only reported case of a patient on guselkumab immunothe…